Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Accendra Health (ACH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Accendra Health (ACH) over the last 17 years, with Q3 2025 value amounting to $32.8 million.

  • Accendra Health's Cash & Equivalents fell 2775.77% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year decrease of 2775.77%. This contributed to the annual value of $27.6 million for FY2024, which is 8865.52% down from last year.
  • Accendra Health's Cash & Equivalents amounted to $32.8 million in Q3 2025, which was down 2775.77% from $38.3 million recorded in Q2 2025.
  • Over the past 5 years, Accendra Health's Cash & Equivalents peaked at $286.3 million during Q2 2023, and registered a low of $27.6 million during Q4 2024.
  • For the 5-year period, Accendra Health's Cash & Equivalents averaged around $111.2 million, with its median value being $59.4 million (2025).
  • As far as peak fluctuations go, Accendra Health's Cash & Equivalents soared by 40758.25% in 2023, and later plummeted by 8865.52% in 2024.
  • Accendra Health's Cash & Equivalents (Quarter) stood at $55.7 million in 2021, then grew by 24.69% to $69.5 million in 2022, then skyrocketed by 249.86% to $243.0 million in 2023, then plummeted by 88.66% to $27.6 million in 2024, then rose by 19.1% to $32.8 million in 2025.
  • Its Cash & Equivalents stands at $32.8 million for Q3 2025, versus $38.3 million for Q2 2025 and $59.4 million for Q1 2025.